The international current market for breast cancer medication is escalating steadily due to mounting patient population, introduction of new medication and profits expansion of Perjeta and Kadcyla. The most up-to-date biotechnology current market report from TrendForce states that the international current market scale of breast cancer medication arrived at US$eleven.97 billion in 2016 and is forecast to broaden at a CAGR of 9.3% to US$22.35 billion in 2023.
Centered on the surface area antigens of tumor cells, breast cancers are classified into 3 subtypes – HER2-positive, HR-positive and triple-negative. The current market for medication treating HER2-positive breast cancers has been escalating swiftly, driven by the escalating profits of Kadcyla and Perjeta worldwide. The international current market scale of HER2-positive medication was around US$7.41 billion in 2016, and TrendForce projects that it will arrive at U$twelve.42 billion in 2023 with the CAGR in the course of the 2016~2023 period at about 7.7%.
Also, the current market for HR-positive and triple-negative breast cancer medication will continue to keep booming more than the subsequent many years as profits of Ibrance are envisioned to remain robust and new medication such as CDK4/6 inhibitors enter the current market. In accordance to TrendForce’s evaluation, the international current market scale of HR-positive and triple-negative breast cancer medication arrived to US$four.fifty six billion in 2016 and is going to broaden at a CAGR of eleven.8% to arrive at US$9.93 billion in 2023.
Sean Liu, TrendForce’s affiliate study manager for biotechnology sector, pointed out that several pharmaceutical companies are attracted by the chances in the breast cancer current market, which has an monumental patient population. “A massive share of the quite a few medical answers are for treating HER2-positive and the HR-positive subtypes,” mentioned Liu. “Recently, pharmaceutical companies have regarded that there is unmet medical need to have for effective solutions linked to triple-negative and BRCA subtypes of breast cancer. PI3K and PARP inhibitors, together with many new medication, have been created to tackle this need. These medication are now entering phase III medical trials and are envisioned to arrive on the current market within just these 3 years.”